Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Asante Appiah, Ernest ^a   Curry, Stephanie ^a   McMonagle, Patricia ^a   Ingravallo, Paul ^a   Chase, Robert ^a   Nickle, David ^a   Qiu, Ping ^a   Howe, Anita ^a   Lahser, Frederick C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiviral; Antiviral agents; Drug resistance mechanisms; Elbasvir; Genotype 4; Grazoprevir; HCV; Hepatitis C virus; NS3 4A; NS5A; Resistance

Indexed keywords

ELBASVIR; GRAZOPREVIR; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; NS3-4A SERINE PROTEASE, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; SERINE PROTEINASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DRUG SCREENING; EC50; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; REPLICON; REPLICON CELL; TRANSIENT EXPRESSION; ANTAGONISTS AND INHIBITORS; CHRONIC HEPATITIS C; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS;

ANTIVIRAL AGENTS; BENZOFURANS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMIDAZOLES; PROTEASE INHIBITORS; QUINOXALINES; REPLICON; SERINE PROTEASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85022067090     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00363-17     Document Type: Article

References (36)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57. https://doi.org/10.1016/j.jhep.2014.07.027.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342. https://doi.org/10.1002/hep.26141.
3. World Health Organization. 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/.
4. Bastos J, Padilla M, Caserta L, Miotto N, Vigani A, Arns C. 2016. Hepatitis C virus: promising discoveries and new treatments. World J Gastroenterology 22:6393–6401. https://doi.org/10.3748/wjg.v22.i28.6393.
5. Messina J, Humphreys I, Flaxman A, Brown A, Cooke G, Pybus O, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87. https://doi.org/10.1002/hep.27259.
6. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318–327. https://doi.org/10.1002/hep.26744.
7. Merck & Co, Inc. 2016. Zepatier™ (elbasvir and grazoprevir) tablets, for oral use. Initial US approval. Merck & Co, Inc, Kenilworth, NJ.
8. Gilead Sciences, Inc. 2015. Harvoni™ (ledipasvir and sofosbuvir) tablets, for oral use. Prescribing information. Gilead Sciences, Inc, Foster City, CA.
9. Willemse SB, Baak L, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JT, Depla AC, Tuynman H, van Nieuwkerk CM, Schinkel CJ, Kwa D, Reesink HW, van der Valk M. 2016. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat 23: 950–954. https://doi.org/10.1111/jvh.12567.
10. Hezode C, Abergel A, Chas J, Conti F, Cotte L, Tateo M, Alric L, Vergniol J, Tomei C, Bernard P-H, Loustaud-Ratti V, Arpurt J-P, Blaison D, Larrey D, Fedchuk L, Bennai Y, Filipovics A, Fontaine H, Pageaux G-P. 2019. Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5, and 6. J Hepatol 64:S755. https://doi.org/10.1016/S0168-8278(16)01471-9.
11. AbbVie, Inc. 2015. Technivie (ombitasvir/paritaprevir/ritonavir), copack-aged for oral use. Initial US approval. AbbVie, Inc, North Chicago, IL.
12. Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, Strickland GT, Loffredo C, Albert J, Widell A. 2007. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 88:1526–1531. https://doi.org/10.1099/vir.0.82626-0.
13. Harper S, McCauley J, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, Nizi E, Carroll SS, Ludmerer SW, Burlein C, DiMuzio JM, Graham DJ, McHale CM, Stahlhut MW, Olsen DB, Monteagudo E, Cianetti S, Giuliano C, Pucci V, Trainor N, Fandozzi CM, Rowley M, Coleman PJ, Vacca JP, Summa V, Liverton NJ. 2012. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 3:332–336. https://doi.org/10.1021/ml300017p.
14. Summa V, Ludmerer S, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2014. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161–4167. https://doi.org/10.1128/AAC.00324-12.
15. Kolykhalov A, Mihalik K, Feinstone SM, Rice CM. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 74:2046–2051. https://doi.org/10.1128/JVI.74.4.2046-2051.2000.
16. Coburn CA, Meinke P, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW. 2013. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 8:1930 –1940. https://doi.org/10.1002/cmdc.201300343.
17. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM. 2014. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:453–462. https://doi.org/10.1053/j.gastro.2014.04.021.
18. Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E. 2016. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 60:2954–2964. https://doi.org/10.1128/AAC.00051-16.
19. Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DeNubile MJ, Howe AY. 2015. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59:6922–6929. https://doi.org/10.1128/AAC.01390-15.
20. Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’Rear JJ, Harrington PR. 2017. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology 152:586–597. https://doi.org/10.1053/j.gastro.2016.10.017.
21. Jacobson IM, Asante-Appiah E, Wong P, Black T, Howe A, Wahl J, Robertson MN, Nguyen B-Y, Shaughnessy M, Hwang P, Barr E, Hazuda D. 2015. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 62:LB-22.
22. Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. 2017. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol https://doi.org/10.1016/j.jhep.2017.01.007.
23. Kamal SM, Nasser I. 2007. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 47:1371–1383. https://doi.org/10.1002/hep.22127.
24. Jensen SB, Serre S, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. 2015. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59:7426–7436. https://doi.org/10.1128/AAC.01953-15.
25. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. 2016. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 165:625–634. https://doi.org/10.7326/M16-0816.
26. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. 2015. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV 2:e319–e327. https://doi.org/ 10.1016/S2352-3018(15)00114-9.
27. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1–13. https://doi.org/10.7326/M15-0785.
28. Hathorn E, Elsharkawy A. 2016. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastro 3:e000112. https://doi.org/10.1136/bmjgast-2016-000112.
29. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 77:177–185. https://doi.org/10.1016/j.antiviral.2007.11.010.
30. Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5:113. https://doi.org/10.1186/1471-2105-5-113.
31. Guindon S, Dufayard J, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307–321. https://doi.org/10.1093/sysbio/syq010.
32. Kampstra P. 2008. Beanplot: a boxplot alternative for visual comparison of distributions. J Statistical Software 28:1. https://doi.org/10.18637/jss.v028.c01.
33. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70: 28–38. https://doi.org/10.1016/j.antiviral.2005.12.003.
34. Gu Z, Graci J, Lahser F, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM. 2013. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein. Antimicrob Agents Chemother 57: 3250 –3261. https://doi.org/10.1128/AAC.00527-13.
35. Saeed M, Scheel T, Gottwein J, Marukian S, Dustin L, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56:5365–5373. https://doi.org/10.1128/AAC.01256-12.
36. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM. 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140:667–675. https://doi.org/10.1053/j.gastro.2010.10.056.